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Background: Blood biomarkers may aid in recruitment to clinical trials of Alzheimer’s
disease (AD) modifying therapeutics by triaging potential trials participants for amyloid
positron emission tomography (PET) or cerebrospinal fluid (CSF) Aβ and tau tests.
Objective: To discover a plasma proteomic signature associated with CSF and PET
measures of AD pathology.
Methods: Liquid chromatography-tandem mass spectrometry (LC-MS/MS) based
proteomics were performed in plasma from participants with subjective cognitive decline
(SCD), mild cognitive impairment (MCI), and AD, recruited to the Amsterdam Dementia
Cohort, stratified by CSF Tau/Aβ42 (n = 50). Technical replication and independent
validation were performed by immunoassay in plasma from SCD, MCI, and AD
participants recruited to the Amsterdam Dementia Cohort with CSF measures (n = 100),
MCI participants enrolled in the GE067-005 study with [18F]-Flutemetamol PET amyloid
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measures (n = 173), and AD, MCI and cognitively healthy participants from the EMIF
500 study with CSF Aβ42 measurements (n = 494).
Results: 25 discovery proteins were nominally associated with CSF Tau/Aβ42 (P < 0.05)
with associations of ficolin-2 (FCN2), apolipoprotein C-IV and fibrinogen β chain
confirmed by immunoassay (P < 0.05). In the GE067-005 cohort, FCN2 was nominally
associated with PET amyloid (P < 0.05) replicating the association with CSF Tau/Aβ42.
There were nominally significant associations of complement component 3 with PET
amyloid, and apolipoprotein(a), apolipoprotein A-I, ceruloplasmin, and PPY with MCI
conversion to AD (all P < 0.05). In the EMIF 500 cohort FCN2 was trending toward a
significant relationship with CSF Aβ42 (P ≈ 0.05), while both A1AT and clusterin were
nominally significantly associated with CSF Aβ42 (both P < 0.05).
Conclusion: Associations of plasma proteins with multiple measures of AD pathology
and progression are demonstrated. To our knowledge this is the first study to report
an association of FCN2 with AD pathology. Further testing of the proteins in larger
independent cohorts will be important.
Keywords: Alzheimer’s disease, amyloid, tau, biomarkers, proteomics, plasma, blood, ficolin-2
INTRODUCTION
The accumulation of amyloid-beta (Aβ) plaques followed by the
deposition of hyper-phosphorylated tau protein in neurofibrillary
tangles, central to Alzheimer’s disease (AD) neuropathology, is
thought to develop around 20 to 30 years in advance of clinical
symptom onset (Jansen et al., 2015). Given the long prodromal
phase of the disease, a biomarker of these early neuropathological
changes would be beneficial in participant selection and cohort
enrichment for clinical trials of disease modifying therapies
targeting AD neuropathology.
To date the best characterized and most frequently used
biomarkers relating to amyloid and tau pathology are PET
imaging measures of brain amyloid deposition and cerebrospinal
fluid (CSF) measures of Aβ, total tau (tTau) and phospho-tau
(pTau) (Kang et al., 2013; Palmqvist et al., 2015). However, PET
scans can be expensive and access to scanners and radioligands
remains limited, whilst extracting CSF is relatively invasive
and can therefore be problematic to obtain, particularly if
repeated measures are required. Blood based biomarkers have
therefore been investigated as a less invasive and potentially
cost-effective option for early detection and monitoring of AD
pathology.
Many studies have investigated blood-based proteomic
biomarkers to distinguish Alzheimer’s disease cases from
cognitively healthy elderly controls as reviewed (Thambisetty
and Lovestone, 2010; Fu et al., 2014). However, to date there
has been a relatively low rate of replication of these biomarkers
across the field. This may be in part due to issues surrounding
a study design that compares AD to cognitively healthy elderly
control subjects. Given that AD neuropathology precedes clinical
presentation of the disease by a number of years, some cognitively
healthy elderly subjects may in fact be harboring silent AD
neuropathology. This reduces the ability to find biomarkers
specifically relating to AD using this design, as some control
subjects will instead be preclinical cases. To overcome this
issue biomarkers specific to the underlying disease have been
sought including candidates relating to rate of cognitive decline,
progression from mild cognitive impairment (MCI) to AD or
disease pathology (MRI measures of brain atrophy, measures
of brain amyloid) as we have reviewed earlier (Baird et al.,
2015).
In such studies predicated not on disease category but on
‘endophenotypes’ of disease, our group has previously identified
protein markers in blood relating to brain atrophy, disease
severity and progression and to accumulation of cerebral amyloid
as measured using PET imaging (Thambisetty et al., 2010; Kiddle
et al., 2012; Hye et al., 2014; Sattlecker et al., 2014; Ashton
et al., 2015; Voyle et al., 2015; Westwood et al., 2016). This
has included the identification of a panel of 10 proteins, which
coupled with APOE genotype, could predict MCI conversion
to AD with 87% accuracy (Hye et al., 2014). Moreover, we
have previously identified a number of proteins associated with
PET amyloid in both an AD based cohort (Ashton et al., 2015)
and in cognitively healthy elderly (Westwood et al., 2016).
Notably, one protein; fibrinogen gamma chain (FGG), when
combined with age was able to predict neocortical amyloid
burden with 59% sensitivity and 78% specificity (Ashton et al.,
2015).
However to date we are not aware of any studies that have
been designed to discover blood protein biomarkers relating to
CSF measures of AD pathology including both measures of Aβ42
and of tau. Therefore, in the present study we first sought to
discover and then to perform a technical replication of candidate
biomarkers correlating with and predicting CSF Tau/Aβ42
pathology in samples collected in the Amsterdam Dementia
Cohort at VU University medical center, using an untargeted
mass spectrometry proteomic approach. Secondly, we aimed
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to validate these candidates by relating their levels to disease
pathology and progression in two independent cohorts. Firstly,
we utilized plasma from people with MCI who were also assessed
with brain amyloid PET using [18F]Flutemetamol [GE067-
005 study (Wolk et al., 2018)], measuring in these samples
both the proteins identified in discovery and replication phase
and protein markers of endophenotypes identified previously
in the studies referenced above. Secondly, we utilized plasma
from AD, MCI and cognitively healthy control individuals
sourced through the European Medical Information Framework
(EMIF) platform1 who also had a CSF Aβ42 measure, here
we focused on measuring protein markers of AD pathology
identified in the discovery and replication phase and also
from our previous studies. Our overall aim was identification,
replication and validation of blood markers indicative of brain
pathology that might be used to reduce screening failure
when seeking to recruit people with pathology to clinical
trials.
MATERIALS AND METHODS
Study Participants, Assessments, Blood
Collection and Processing
Amsterdam Dementia Cohort
Biomarker discovery proteomics were performed on plasma
samples from participants with AD, MCI or with mild
subjective cognitive decline (SCD) visiting the Alzheimer Center
Amsterdam as previously described (van der Flier et al., 2014;
van der Flier and Scheltens, 2018). In brief, the diagnosis
of probable AD was made according to common clinical
and research criteria (McKhann et al., 1984, 2011), for MCI
the Petersen’s criteria was used (Petersen et al., 1999) and
SCD was assigned to patients who presented with cognitive
complaints but did not meet the criteria for dementia, MCI or
any neurological or psychiatric conditions affecting cognition
(van der Flier et al., 2014). Venous blood samples were
processed for plasma and stored according to international
consensus standard operating procedures (Teunissen et al.,
2009).
Plasma samples were selected on the basis of CSF Aβ42
and tau measures and, using an extreme phenotype approach,
were stratified as very low CSF pathology (low CSF tau/high
CSF Aβ42, n = 25) to very high CSF pathology (high
CSF tau/low CSF Aβ42, n = 25) (Table 1). Calculation
of the CSF pathology score was carried out using the
discrimination line: x = (373 + 0.82[tau])/[Aβ42] (Mulder et al.,
2010).
Replication studies using immunocapture techniques of the
biomarkers identified in the discovery phase were carried out
in the plasma samples included in the discovery phase and in
additional plasma samples from a further 50 subjects visiting the
Alzheimer Center Amsterdam, also stratified by CSF pathology
score (Mulder et al., 2010). In total 50 plasma samples per group
were included in the replication phase (Table 1). Data from
1www.emif.eu
clinical assessments were available for all subjects including mini
mental state examination (MMSE) and Apolipoprotein E (APOE)
genotype data (van der Flier et al., 2014).
GE067-005 Study
Plasma samples from MCI participants enrolled in the GE067-
005 study2 (Wolk et al., 2018) were included in the independent
validation study (n = 173, Table 2). This included amnestic
MCI subjects who converted to probable AD within a 3-
year time frame (MCI Converter, n = 52) and subjects who
remained MCI over this time period (MCI non-converter,
n = 121). Participants were assessed clinically every 6 months
until conversion, dropout or completion of the 3-year follow-up.
[18F]Flutemetamol PET amyloid imaging data were available for
all subjects, who were categorized as having either an “abnormal”
PET amyloid scan (positive for the presence of amyloid, n = 68)
or a “normal” PET amyloid scan (negative for the presence of
amyloid, n = 105). Visual image interpretation of the PET scan
was performed by five independent trained readers who were
blinded to the participants’ clinical history and diagnosis. Scan
interpretation was based on the majority classification from these
five independent readers. The details of image interpretation are
published elsewhere (Wolk et al., 2018). General clinical and
demographic data were also available for all subjects, including
APOE genotype, body mass index (BMI), prevalence of diabetes
and years of education. Whole blood was collected in EDTA tubes
and processed for plasma (Supplementary Methods Section 1).
EMIF 500 Study
The EMIF (see text footnote 1) is a precompetitive, public-
private Innovative Medicines Initiative funded platform
facilitating access to cohort studies and real world observational
data from across Europe. We used EMIF to identify three cohorts
with samples suitable for validation studies. Plasma samples
from AD, MCI and cognitively healthy participants (CTL), for
whom a measure of CSF Aβ42, tTau and pTau was available,
were included in this independent validation study (n = 494,
Table 3). Participants were recruited by three separate centers;
Clinica Neurologica, Universita di Perugia (n = 252), Hospital
Sant Pau, Barcelona (n = 154) and the Alzheimer Unit of
Fondazione Ca Granda, IRCCS Ospedale Maggiore Policlinico,
Milan (n = 88). Diagnoses were made according to standard
criteria (McKhann et al., 1984, 2011; Petersen et al., 1999) and
general clinical and demographic information were available for
all subjects (including MMSE and APOE genotype data). CSF
Aβ42, tTau and pTau cut-off values for assigning high and low
categories were provided by each individual cohort; Perugia,
Aβ42 = 800 pg/mL, tTau = 300 pg/mL, pTau = 60 pg/mL
(Majbour et al., 2017); Barcelona; Aβ42 = 550 pg/mL,
tTau = 350 pg/mL, pTau = 61 pg/mL (Alcolea et al., 2015); and
Milan, Aβ42 = 600 pg/mL, tTau = 450 pg/mL, pTau = 61 pg/mL
(Galimberti et al., 2014). CSF Aβ42, tTau and pTau values
across cohorts were combined into continuous variables using
z-scoring. For each CSF measure, Z-scores were calculated
2https://clinicaltrials.gov/ct2/show/NCT01028053
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TABLE 1 | Demographics of subjects from the Amsterdam Dementia Cohort.
Variable Subjects included in LC-MS/MS discovery Subjects included in ELISA technical replication
Low CSF pathology High CSF pathology P-value Low CSF pathology High CSF pathology P-value
N 25 25 / 50 50 /
CSF pathology = (373+0.82[tau])/[Aβ42] 0.56 ± 0.05 3.63 ± 0.49 <0.001∗ 0.54 ± 0.05 3.45 ± 0.82 <0.001∗
Age (years) 65.84 ± 3.80 65.01 ± 3.81 0.648 63.74 ± 4.51 64.21 ± 4.13 0.549
Female gender N (%) 10 (40) 11 (44) 0.777 21 (42) 27 (54) 0.232
Clinical diagnosis
SCD N (%) 16 (64) 2 (8) / 41 (82) 5 (10) /
MCI N (%) 8 (32) 7 (28) / 8 (16) 7 (14) /
AD N (%) 1 (4) 16 (64) / 1 (2) 38 (76) /
APOE genotype ε4+ N (%) 6 (24) 18 (72) <0.01∗ 16 (32) 30 (60) <0.01∗
MMSE 28 ± 2 25 ± 2 <0.001∗ 28 ± 2 22 ± 6 <0.001∗
CSF, cerebrospinal fluid; SCD, subjective cognitive decline; MCI, mild cognitive impairment; AD, Alzheimer’s disease; APOE, apolipoprotein E; MMSE, mini-mental state
examination. Mean ± SD. ∗Statistically significant.
TABLE 2 | Demographics of the subjects from the GE067-005 study.
Variable GE067-005 subjects grouped by PET amyloid GE067-005 subjects grouped by MCI conversion
Low [18F] PET amyloid High [18F] PET amyloid P-value MCI non-converters MCI converters P-value
N 105 68 / 121 52 /
High PET amyloid N (%) / / / 36 (30) 32 (62) <0.001∗
PET uptake value 1.25 ± 0.14 2.05 ± 0.36 <0.001∗ 1.46 ± 0.41 1.81 ± 0.50 <0.001∗
MCI converter N (%) 20 (19) 32 (47) <0.001∗ / / /
Age (years) 69.13 ± 8.73 73.37 ± 7.64 <0.01∗ 69.36 ± 8.39 74.15 ± 8.04 <0.01∗
Female gender N (%) 50 (48) 37 (54) 0.384 59 (49) 28 (54) 0.541
BMI 27.42 ± 4.73 25.63 ± 3.47 <0.05∗ 26.86 ± 4.63 26.39 ± 3.64 0.916
Education (years) 13.28 ± 3.54 13.72 ± 4.11 0.706 13.21 ± 3.63 14.00 ± 4.07 0.135
Diabetes N (%) 9 (9) 5 (7) 0.775 10 (8) 4 (8) 0.900
APOE genotype ε4+ N (%) 23 (22) 41 (60) <0.001∗ 37 (31) 27 (52) <0.01∗
PET, [18F]-flutemetamol positron emission tomography; MCI, mild cognitive impairment; BMI, body mass index; APOE, apolipoprotein E. Mean ± SD. ∗Statistically
significant.
TABLE 3 | Demographics of the subjects from the EMIF 500 study.
Variable EMIF 500 subjects grouped by CSF Aβ42
Low CSF Aβ42 High CSF Aβ42 P-value
N 198 294 /
Age (years) 66.21 ± 9.73 69.76 ± 8.81 <0.001∗
Female gender N (%) 112 (57) 167 (57) 0.959
AD N (%) 9 (5.6) 152 (94.4) /
MCI N (%) 116 (49.6) 118 (50.4) /
CTL N (%) 73 (75.3) 24 (24.7) /
APOE genotype ε4+ N (%) 43 (22) 147 (50) <0.001∗
MCI, mild cognitive impairment; APOE, apolipoprotein E. Mean ± SD. ∗Statistically significant.
independently for each cohort before being combined into one
variable.
Discovery Phase: Gel LC-MS/Mass
Spectrometry Based Proteomics
Discovery proteomics was carried out by gel LC-MS/Mass
Spectrometry (LC-MS/MS) coupled with tandem mass tagging
(TMT). The data acquisition and preprocessing pipelines are
described in detail elsewhere (Ashton et al., 2015). In brief, the
proteomics workflow consisted of plasma samples labeled in
a TMT6plex configuration with TMT126 – TMT130 (Thermo
Fisher Scientific), and the study reference with TMT131. The
tagged samples within each TMT6plex were pooled and then
separated by one-dimensional gel electrophoresis. Ten equal
Frontiers in Aging Neuroscience | www.frontiersin.org 4 December 2018 | Volume 10 | Article 409
fnagi-10-00409 December 8, 2018 Time: 15:6 # 5
Westwood et al. Plasma Biomarkers of Alzheimer’s Pathology
fractions were excised from each gel and the gel pieces were
destained, tryptically digested and peptides extracted. LC-
MS/MS acquisition was performed using the Orbitrap Velos
Pro instrumentation (Thermo Fisher Scientific) coupled to a
Proxeon EASY-nLC II system (Thermo Fisher Scientific). The
LC-MS/MS raw Excalibur data files (Thermo Fisher Scientific)
were processed by Proteome discover (Thermo Fisher Scientific,
version 1.3) using Mascot3 (version 2.3) to determine peptide
identifications. Processing of the Mascot output data files was
performed in R, and included median ratio normalization,
calculation of peptide ratios and subsequent protein scores using
median and mean roll-up methods of peptide ratios as described
(Ashton et al., 2015). Where the same protein was observed by
electrophoresis in multiple different molecular weight regions
of the one-dimensional gel, these observations were treated
as separate protein molecular weight isoforms in subsequent
analysis. Analysis of each protein molecular weight isoform was
performed on the data produced from both the mean and median
protein roll up methods and age, sex, APOE ε4 allele presence and
sample storage duration were included as covariates in regression
models.
Replication Phase: Immunocapture
Assay Based Proteomics
Technical replication was performed on proteins in the same 50
samples that underwent LC-MS/MS based proteomics with an
additional 50 samples selected from the Amsterdam Dementia
Cohort (Table 1). The criteria for protein selection for replication
included; (1) nominal statistical significance, (2) quantification
by ≥2 peptides, and (3) detection by 1D gel electrophoresis in
the molecular weight range of the native protein. Eight proteins
were selected for replication; ficolin-2 (FCN2), apolipoprotein
C-IV (ApoC-IV), c4-binding protein alpha chain (C4BPA),
fibrinogen β chain (FGB), Ig gamma-3 chain C region (IGHG3),
apolipoprotein A-I (ApoA-I), serotransferrin and apolipoprotein
A-IV (ApoA-IV). These proteins included novel candidates
and proteins that had previously been identified in AD based
biomarker studies (Yu et al., 2003; Liu et al., 2006; Thambisetty
et al., 2010; Ijsselstijn et al., 2011; Hu et al., 2012; Song et al., 2012;
Hye et al., 2014; Ashton et al., 2015; Westwood et al., 2016).
Proteins were measured by commercially available single-
analyte enzyme-linked immunosorbent assays (ELISAs)
according to the manufacturer’s instructions (Supplementary
Table 1). ELISA absorbance at 450 nm was detected using a
microplate reader (PHERAstar FS, BMG, LABTECH). The
background corrected (570 nm) absorbance data were exported
into Sigma Plot (Systat Software; version 12.5) for estimation
of protein concentrations using a 5-parameter logistic fit. Intra-
assay and inter-assay variability was assessed by calculation of the
percentage coefficient of variation (% CV). Average intra-assay
CVs were calculated using the duplicate measures for each
sample and average inter-assay CV was calculated using the
measurement of a control sample, which was analyzed on each
plate. All protein concentration values were log10 transformed
prior to statistical analysis and age, sex, APOE ε4 allele presence,
3http://www.matrixscience.com
plate batch and sample storage duration were included as
covariates in regression models.
Independent Validation Phase
Proteins were selected from the replication phase in the
Amsterdam Dementia Cohort, based upon nominal statistical
significance, for further extension studies using the GE067-
005 cohort. In addition, other proteins previously identified as
markers related to AD pathology and progression, including
candidate markers of MCI conversion to AD (Hye et al.,
2014), rates of cognitive decline and disease severity and brain
atrophy (Hye et al., 2014; Sattlecker et al., 2014) and [11C]
Pittsburgh compound B (PiB) PET amyloid (Kiddle et al.,
2012; Ashton et al., 2015; Voyle et al., 2015; Westwood et al.,
2016) were also selected (Supplementary Table 2). In total
37 targets (including alpha-2-macroglobulin measured by two
different assays) were measured in the GE067-005 study cohort
(Supplementary Table 2). Of these, twenty-six proteins were
measured by multiplex bead assays across 7 MagPlex MAP
panels using the Luminex 200 instrument (Supplementary
Table 1). Median fluorescent intensity (MFI) was measured using
xPONENT 3.1 (Luminex Corporation). Eleven proteins were
quantified by commercially available ELISAs as described earlier
(Supplementary Table 1). Intra-assay and inter-assay variability
was calculated as described earlier. All protein concentration
values were log10 transformed prior to statistical analysis in order
to achieve a normal distribution and the following covariates
were included in regression models: age, sex, APOE ε4 allele
presence, BMI, diabetes, center, batch variation and sample
storage duration.
Proteins were also selected from our earlier discovery studies
for independent validation in the EMIF 500 study cohort. In total
21 proteins were measured by multiplex bead assays using the
Luminex 200 instrument and by commercially available ELISAs
as described earlier (Supplementary Table 1). As plasma proteins
were measured in singular, the data were assessed for outliers on a
protein-by-protein basis. Extreme outliers were defined as values
falling outside three times the inter-quartile range of all samples
measured and were removed from the dataset prior to subsequent
statistical analysis. The following covariates were included in
regression models: age, sex, APOE ε4 allele presence, center, and
batch variation.
Statistical Procedures
Univariate Statistical Analysis
All statistical analyses were performed in R (version 1.3.3). For
both discovery and replication phase studies, proteomic data
were analyzed using the Mann Whitney U-test and logistic
regression to compare dichotomized high and low CSF pathology
groups. The association between proteomic data and continuous
measures of CSF Tau/Aβ42 were assessed by Spearman rank
correlation and linear regression. Validation phase studies
were analyzed by both linear and logistic regression to assess
the relationship between the proteomic data and pathology
endophenotypes when accounting for covariates. Benjamini-
Hochberg q values were calculated as a multiple testing correction
for all analyses.
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Classification Analysis for the Prediction of Amyloid
Status
A generalized linear regression model (GLM) was used to adjust
the data for covariates. Machine learning (i.e., classification) was
performed in R on the GLM adjusted data. The minimal protein
set with optimal AUC characteristics for prediction of amyloid
status were assessed by Support Vector Machines combined with
LASSO, as a variable selection method, and performance was
assessed using 100 repeats of 10-fold cross validation.
Pathway Analysis: Using LC-MS/MS Proteomic Data
Differential regulation of pathways associated with CSF Tau/Aβ42
pathology were identified through gene enrichment analysis
on the results of the LC-MS/MS analysis. For this analysis
only protein molecular weight isoforms detected in 80% or
more of the TMT6plexs and for which gene IDs were available
were included. The p-values derived from the univariate
analysis of the protein molecular weight isoforms were
used to estimate a single p-value per protein by applying
Fisher’s method as described here. For each protein the sum
of logarithms of the p-values of all the molecular weight
isoforms were calculated. The chi-squared distribution was
then used to derive the protein p-value from this sum of
logarithms.
We next expanded the analysis to include proteins that
directly interact with the proteins detected in 80% or more
of the TMT6plexs. Firstly, the p-values were log transformed
and then the proteins known to interact with these proteins
were identified by STRING (Szklarczyk et al., 2015). Only the
most stringent protein-protein interactions (that have direct
experimental evidence) were considered, with a confidence level
>0.4. For each STRING protein, the average of the normalized
p-values of the proteins that directly interact with them was then
calculated.
Enrichment analysis on the expanded list proteins was
performed using the Kolmogorov Smirnov test (KS test) with
gene-lists corresponding to pathways [Reactome; (Joshi-Tope
et al., 2005)], diseases [DisGeNet; (Pinero et al., 2015)], and
GWAS studies [GWAS catalog; (Welter et al., 2014)]. The
p-values were corrected with a permutation test of 50,000
iterations.
RESULTS
In order to identify a biomarker that might predict brain
amyloid pathology we performed a proteomic study in three
phases in three independent sample collections. First, we
used mass-spectrometry based discovery in the Amsterdam
Dementia Cohort including a technical replication phase using
immunocapture. Then we used immunocapture to replicate these
and previous findings in a cohort derived from a clinical trial
of a radiotracer for detection of brain amyloid (GE067-005
study) and finally an independent validation phase study, again
using immunocapture methods in an independent set of samples
collated from three separate cohorts sourced using the EMIF. The
study workflow is illustrated in Figure 1.
Discovery Phase: Gel LC-MS/MS Based
Proteomics in the Amsterdam Dementia
Cohort
Using multiplexed mass spectrometry, we identified 804 protein
MW isoforms, constituting 249 unique known protein groups
from the combined MS/MS runs (Supplementary Table 3).
Of these proteins, 253 protein MW isoforms, consisting of
85 unique protein groups were identified in 80% or more of
TMT6plex’s (Supplementary Table 4). 42 protein MW isoforms
corresponding to 25 unique proteins passed 1 or more statistical
tests assessing the relationship with CSF pathology group or
continuous measures of CSF Tau/Aβ42 (all nominal P < 0.05,
Supplementary Table 5).
Replication Phase: Immunocapture
Assay Based Proteomics in the
Amsterdam Dementia Cohort
In order to further assess these discovery phase observations,
we performed a combined technical and clinico-biological
replication study for eight proteins. Intra-assay CV was <13%
for all assays, and batch variation was included as a covariate in
regression analysis to control for any inter-assay differences.
Apolipoprotein C-IV was nominally significantly increased in
the high CSF Tau/Aβ42 pathology group compared to the low
CSF Tau/Aβ42 pathology group by logistic regression (β = 0.665,
P < 0.05; Table 4). ApoC-IV, FGB and FCN2 were also
positively correlated with CSF Tau/Aβ42 by Spearman rank
correlation (r = 0.237, P < 0.05, Figure 2A; and r = 0.228,
P < 0.05, Figure 2B; r = 0.214, P < 0.05, Figure 2C,
respectively, Table 4), replicating the results observed in the
LC-MS/MS discovery data. Correlations of ApoC-IV and FGB
with the separate CSF measures of Aβ42 and pTau were also
observed by Spearman’s rank correlation and linear regression
(Supplementary Table 6). ApoC-IV was negatively associated
with CSF Aβ42 by both linear regression and spearman
rank correlation (β = −101.867, P < 0.01 and r = −0.300,
P < 0.01, respectively) and FGB was positively correlated
with CSF pTau by spearman rank correlation (r = 0.227,
P < 0.05).
Pathway Analysis: LC-MS/MS
Proteomics in the Amsterdam Dementia
Cohort
In order to explore the potential biological significance of these
findings, we then performed a pathway analysis. The total
summed p-values were calculated for 77 proteins from 233
protein MW isoform p-values for inclusion in gene enrichment
analysis. Using STRING this list was expanded to include
proteins for which there is direct experimental evidence of an
interaction, giving a total of 769 proteins. When comparing
this protein set to the Reactome database, three pathways were
significant after FDR correction for multiple comparisons; HDL-
mediated lipid transport (q = 0.010), lipoprotein metabolism
(q = 0.035), and lipid digestion, mobilization, and transport
(q = 0.035) (Table 5). Comparison to the DisGeNet database
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FIGURE 1 | Schematic diagram illustrating the experimental work flow of the present study for the discovery, replication, and validation of plasma proteins
associated with brain pathology. AD, Alzheimer’s disease; MCI, mild cognitive impairment; SCD, subjective cognitive decline; CSF, cerebrospinal fluid; TMT, tandem
mass tagging; LC-MS/MS, liquid chromatography tandem mass spectrometry; Aβ, amyloid-beta.
revealed three diseases were significant post FDR correction;
hypercholesterolemia, familial (q = 0.034), brain diseases
(q = 0.034), and metabolic bone disorder (q = 0.034)
(Table 5).
Independent Validation Phase:
Immunocapture Assay Based
Proteomics in the GE067-005 Study
Cohort
Using immunocapture, we then performed a validation phase
study in an independent cohort using a different end point
measure of AD pathology ([18F]-Flutemetamol PET amyloid).
From 37 proteins measured, three proteins were excluded from
analysis due to technical failure of the assays (Soluble receptor
for advanced glycation end products, Complement C4-B and
IGHG3). Intra-assay CV was<12% for all other assays, and batch
variation was included as a covariate in regression analysis to
control for any inter-assay differences.
Univariate Analysis
Increased FCN2 levels in the [18F]-flutemetamol PET positive
group were observed by logistic regression (β = 0.580, P < 0.05,
Supplementary Table 7), replicating the relationship with
CSF Tau/Aβ42 observed in the Amsterdam Dementia Cohort.
A nominally significant association of Complement C4 with
[18F]-flutemetamol PET amyloid was also observed by both
logistic regression (β = 0.750, P < 0.05, Supplementary
Table 7) and linear regression (β = 0.079, P < 0.05,
Supplementary Table 7). Apolipoprotein(a) [Apo(a)], ApoA-I,
Ceruloplasmin and Pancreatic prohormone were all nominally
associated with MCI conversion to AD by logistic regression
(β = −0.476, P < 0.05; β = 0.631, P < 0.05; β = −0.526,
P < 0.05; β = −0.456, P < 0.05, respectively, Supplementary
Table 8).
Classification Analysis for the Prediction of Amyloid
Status in the GE067-005 Cohort ([18F]-Flutemetamol
PET Group)
After excluding subjects with missing data, the classification
analysis was performed on 78 GE067-005 subjects. These
subjects were split between amyloid-positive and amyloid-
negative groups as follows: negative [18F]-Flutemetamol PET,
n = 44; positive [18F]-Flutemetamol PET, n = 34 as measured
by visual inspection according to the approved methods for
image interpretation. The minimal protein set with optimal AUC
characteristics for prediction of amyloid group was assessed by
SVM combined with LASSO and performance was assessed using
100 repeats of 10-fold cross validation. Two proteins (Aβ40
and ApoC4) formed the minimal protein panel for classifying
amyloid positivity and achieved modest accuracy (AUC = 0.69
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(Figure 3), PPV = 0.52, NPV = 0.51, sensitivity = 0.57, and
specificity = 0.44).
Independent Validation Phase in the
EMIF 500 Study Cohort
Univariate Statistical Analysis of Plasma Proteins in
Relation to CSF Aβ42
In order to explore the relationship between these proteins and
disease we obtained samples from three cohorts sourced through
EMIF and including participants with MCI and AD as well as
normal controls. We first considered the relationship between
plasma proteins and CSF Aβ42 pathology in all AD, MCI and CTL
subjects combined. In the high Aβ42 pathology group a reduction
in A1AT (β = −0.248, P < 0.05, Supplementary Table 9) and
an increase in clusterin (β = 0.278, P < 0.05, Supplementary
Table 9) were observed by logistic regression. There was also a
trend toward increased FCN2 in the high Aβ42 pathology group
(β = 0.216, P = 0.055, Supplementary Table 9). A1AT was also
nominally significantly associated with CSF Aβ42 pathology by
linear regression (β = 31.690, P < 0.05, Supplementary Table 9).
The relationship between the 21 plasma proteins and CSF
Aβ42 were then examined within each of the separate diagnostic
groups (n = 162 AD, n = 235 MCI, n = 97 CTL). In the
AD group, only RANTES was associated with CSF Aβ42, as
shown by both logistic regression (β = −1.192, P < 0.01,
Supplementary Table 10) and linear regression (β = 35.759,
P < 0.05, Supplementary Table 10). In MCI there was an
association of ICAM1 with CSF Aβ42 by linear regression
(β = 66.327, P < 0.01, Supplementary Table 11). In the CTL
group, a significant decrease in CFHR-1 and FGG in association
with high CSF Aβ42 by logistic regression (β = −1.435, P < 0.05
and β =−1.003, P< 0.05, respectively, Supplementary Table 12)
was observed, whilst A1AT was nominally significantly associated
with CSF Aβ42 by both logistic and linear regression (β =−1.186,
P < 0.05 and β = 77.990, P < 0.01, respectively, Supplementary
Table 12).
A trend was also observed for increased FCN2 with
high CSF Aβ42 in the MCI group, by both logistic and
linear regression (β = 0.315, P = 0.058 and β = −42.573,
P = 0.051, respectively, Supplementary Table 11), replicating
the association of FCN2 with CSF Tau/Aβ42 in the Amsterdam
Dementia Cohort and with PET amyloid in MCI in the GE067005
study.
Univariate Statistical Analysis of Plasma Proteins in
Relation to CSF tTau and pTau
We next assessed the relationship of the plasma proteins with
CSF tTau and pTau in all AD, MCI and CTL subjects combined
(n = 494). In the high CSF tTau pathology group, clusterin
and complement C4B were nominally significantly increased
(β = 0.379, P < 0.01 and β = 0.284, P < 0.05, respectively,
Supplementary Table 13) and Complement C4 nominally
significantly decreased (β = −0.269, P < 0.05, Supplementary
Table 13) by logistic regression. Associations with CSF
tTau by linear regression were also observed for clusterin
(β = 42.089, P < 0.05, Supplementary Table 13), complement
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FIGURE 2 | (A) Correlation of APOC-IV rank with CSF Tau/Aβ rank. (B) Correlation of FGB rank with CSF Tau/Aβ rank. (C) Correlation of ficolin-2 rank with CSF
Tau/Aβ rank.
C4 (β = −56.915, P < 0.01, Supplementary Table 13) and Ig
kappa chain C region (β = −37.292, P < 0.05, Supplementary
Table 13). Logistic regression showed a nominally significant
increase in clusterin (β = 0.284, P < 0.05) and nominally
significant reduction of C4 (β = −0.318, P < 0.01) in association
in the high CSF pTau group (Supplementary Table 14).
Associations of clusterin and C4 with CSF pTau were also
observed by linear regression (β = 5.083, P < 0.05, and
β = −5.267, P < 0.05, respectively, Supplementary Table 14).
AGP was also nominally significantly associated with CSF pTau
by linear regression (β = −4.971, P < 0.05, Supplementary
Table 14).
Within the AD group no proteins were associated with CSF
tTau (Supplementary Table 15), whilst FCN2 was nominally
significantly reduced in the high CSF pTau pathology group
by logistic regression (β = −0.678, P < 0.05, Supplementary
Table 18). In the MCI group, clusterin was nominally
significantly increased in the high CSF tTau group (β = 0.409,
P < 0.05, Supplementary Table 16) and C4 was nominally
significantly associated with CSF tTau by both logistic and
linear regression (β = −0.441, P < 0.05 and β = −47.627,
P < 0.05, respectively, Supplementary Table 16). C4 was also
decreased in the high CSF pTau pathology group (β = −0.468,
P < 0.05, Supplementary Table 19). In the control group C4B
was nominally significantly increased in the high CSF tTau
group (β = 1.771, P < 0.05, Supplementary Table 17), whilst
there were no significant associations CSF pTau (Supplementary
Table 20).
Classification Analysis for the Prediction of Amyloid
Status in the EMIF500 Cohort (CSF Aβ42 Group)
After excluding subjects with missing data, the classification
analysis was performed on 96 subjects from the EMIF 500
study. These subjects were roughly evenly split between high
and low amyloid groups (low CSF Aβ42, n = 42; high
CSF Aβ42, n = 54). The minimal protein set with optimal
AUC characteristics for prediction of CSF Aβ42 amyloid was
assessed by SVM combined with LASSO and performance was
assessed using 100 repeats of 10-fold cross validation. Five
proteins (A1AT HAGP, Ig Kappa Chain C region, PEDF, and
RANTES) formed the minimal protein panel for classifying
amyloid positivity and achieved modest accuracy (AUC = 0.67
(Figure 3), PPV = 0.47, NPV = 0.47, sensitivity = 0.55, and
specificity = 0.41).
DISCUSSION
In this study, we describe the discovery, replication and validation
of plasma protein biomarkers relating to AD pathology and
progression using an amyloid and tau pathology endophenotype
based design. The success of recent clinical trials of disease-
modifying therapies targeting Aβ have been hampered by lack of
brain amyloid pathology in clinically diagnosed AD participants
(Salloway et al., 2014) and in future it is likely that many trials
of potential disease modifying agents will utilize biomarkers
such as CSF amyloid and tau and amyloid PET measures of
pathology in participant selection. However, such markers are
relatively invasive and demanding of resource and participant
commitment. Identifying participants with pathology using such
methods in the preclinical and prodromal phase of disease is
difficult and results in high screen failure in clinical trials. The
cost of such screen failure is high, often prohibitively so. Even a
modest reduction in screen failure rates would represent a major
advance, certainly reducing costs and potentially accelerating
speed of recruitment to such trials of disease modifying agents.
Blood based biomarkers that can detect individuals likely to
harbor AD pathology may therefore provide a cost-effective aid
in triaging potential trial participants for PET or CSF based
tests, helping to reduce screen failure, patient burden and costs.
Moreover, a minimally invasive and cost-effective biomarker of
AD pathology may help facilitate trials where repeated testing and
monitoring of pathology is required.
We have first used LC-MS/MS to identify twenty-five plasma
protein biomarkers of CSF Tau/Aβ42, and then replicated by
ELISA the nominal association with CSF Tau/Aβ42 of three of
Frontiers in Aging Neuroscience | www.frontiersin.org 9 December 2018 | Volume 10 | Article 409
fnagi-10-00409 December 8, 2018 Time: 15:6 # 10
Westwood et al. Plasma Biomarkers of Alzheimer’s Pathology
the eight proteins subjected to further analysis; FCN2, ApoC-
IV and FGB chain. Lack of ELISA-based replication of the
remaining five proteins may be in part due to key platform
differences. Mass spectrometry involves the analysis of peptides
resulting from denatured protein, whilst ELISA measures intact
protein, or more precisely the region of the intact protein
where the epitope recognized by the antibody resides. It is
possible therefore that protein region differences in turnover and
abundance and other post-translational modifications including
phosphorylation, glycosylation, and other changes may impact
these results. Further replication studies examining protein
region-specific abundance would therefore be needed to confirm
the association of the proteins with CSF Tau/Aβ42.
Pathway analysis of the LC-MS/MS proteomic data revealed
the significant differential regulation of a number of lipid-
related pathways in association with CSF Tau/Aβ42 pathology.
This is in line with the high representation of apolipoproteins
we observed significantly associated with CSF measures of
TABLE 5 | Pathway analysis of the proteins associated with CSF Tau/Aβ, comparing gene lists corresponding to pathways (Reactome), diseases (DisGeNet), and GWAS
studies (GWAS catalog).
Database # Pathway name P-value
FDR corrected (q-value) Uncorrected
Reactome
R-HSA-194223 HDL-mediated lipid transport 0.0104 0.0001
R-HSA-174824 Lipoprotein metabolism 0.0347 0.0009
R-HSA-73923 Lipid digestion, mobilization, and transport 0.0347 0.0010
R-HSA-174800 Chylomicron-mediated lipid transport 0.1404 0.0054
R-HSA-196741 Cobalamin (Cbl, vitamin B12) transport and metabolism 0.2149 0.0124
R-HSA-174577 Activation of C3 and C5 0.2149 0.0189
R-HSA-196791 Vitamin D (calciferol) metabolism 0.2149 0.0196
R-HSA-975634 Retinoid metabolism and transport 0.2149 0.0198
R-HSA-381426 Regulation of Insulin-like Growth Factor transport and uptake by Insulin-like Growth Factor Binding Proteins 0.2149 0.0206
R-HSA-556833 Metabolism of lipids and lipoproteins 0.2149 0.0207
UMLS # Disease name P-value
FDR corrected (q-value) Uncorrected
DisGeNet
C0020445 Hypercholesterolemia, familial 0.0344 0.0005
C0006111 Brain diseases 0.0344 0.0009
C0005944 Metabolic bone disorder 0.0344 0.0013
C0020476 Hyperlipoproteinemias 0.0569 0.0032
C0020615 Hypoglycemia 0.0569 0.0036
C0497327 Dementia 0.0569 0.0046
C0017661 IGA glomerulonephritis 0.0569 0.0052
C0030567 Parkinson disease 0.0569 0.0058
C0035126 Reperfusion injury 0.0569 0.0062
C0005612 Birth weight 0.0647 0.0085
EFO/GO# Trial name P-value
FDR corrected (q-value) Uncorrected
GWAS Catalog
EFO 0004571 Butyrylcholinesterase measurement 0.0721 0.0047
EFO 0000319 Cardiovascular disease 0.0721 0.0090
EFO 712 Stroke 0.0721 0.0092
EFO 3892 Pulmonary function measurement 0.0721 0.0122
EFO 0004746 Lipoprotein-associated phospholipase a(2) measurement 0.0721 0.0215
EFO 0004723 Coronary artery calcification 0.0721 0.0219
EFO 0004214 Abdominal aortic aneurysm 0.0721 0.0235
EFO 0004624 Prostate specific antigen measurement 0.0721 0.0241
GO 0042493 Response to drug 0.0721 0.0295
EFO 0004461 Iron biomarker measurement 0.0721 0.0374
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FIGURE 3 | (A) Performance of SVM classifiers built using n = 1–33 proteins, ranked by LASSO and with 100 repeats of 10-fold cross validation. Two proteins were
the minimal protein set with optimal AUC for classifying [18F]-Flutemetamol PET positivity in the GE067-005 cohort. (B) Receiver operating characteristics (ROC)
curve obtained for the minimal two protein classifier (Aβ40 and ApoC4) for prediction of [18F]-Flutemetamol PET positivity in the GE067-005 cohort. (C) Performance
of SVM classifiers built using n = 1–20 proteins, ranked by LASSO and with 100 repeats of 10-fold cross validation. Five proteins were the minimal protein set with
optimal AUC for classifying CSF Aβ42 positivity in the EMIF 500 cohort. (D) ROC curve obtained for the minimal five protein classifier (A1AT, HAGP, Ig Kappa chain C
region, PEDF, and RANTES) for prediction of CSF Aβ42 positivity in the EMIF 500 cohort.
pathology. Furthermore, these findings are in agreement with
the alteration to brain lipid metabolism observed in AD
(Bales, 2010) and with pathway analysis of genomic association
data (Jones et al., 2010). The proteins significantly associated
with CSF measures of AD pathology were also shown to
be associated with three disease groups using informatics
approaches; familial hypercholesterolemia, brain diseases and
metabolic bone disorder. These findings support the previously
documented association of cholesterol and hypercholesterolemia
with AD pathology (Refolo et al., 2000; Gibson Wood et al., 2003)
and the association of osteoporosis with risk of developing AD
(Zhou et al., 2014).
The most striking finding from all three phases of the current
study – discovery, replication and validation – is the nominal
association of FCN2 with AD pathology measures. This finding
was consistent across measures used to assess pathology (CSF
and PET) and using independent or orthogonal protein assay
technologies (mass spectrometry and ELISA). Moreover, the
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association of FCN2 with CSF Aβ42 but not CSF Tau or pTau
in the Amsterdam Dementia Cohort, suggests that this is driven
by an association with amyloid pathology, in line with the
replication results we report here from the GE067-005 PET
amyloid study. However, in the EMIF500 cohort we do see
a significant association of FCN2 with pTau. However, this
association is only found in AD subjects, whereas earlier in the
disease course we see a trend toward a significant relationship
between FCN2 and CSF Aβ42 in the MCI subjects from this
cohort. Given the studies that suggest CSF biomarkers are more
sensitive to early change than PET biomarkers (Toledo et al.,
2015) it might be that change in FCN2 measures could follow
change in amyloid pathology particularly in the preclinical and
prodromal stages of the disease. Such a hypothesis emphasizes
the need for longitudinal studies of biomarkers in AD.
To our knowledge this is the first study to identify and
validate FCN2 as a biomarker of AD pathology. Ficolins and
mannose-binding lectins (MBL) are both activators of the lectin
complement pathway (Fujita et al., 2004) and CSF MBL levels
have been shown to be reduced in AD (Lanzrein et al., 1998).
Another member of the ficolin family; ficolin-3 (FCN3), which
shares approximately 50% amino acid sequence homology with
FCN2 (Kilpatrick and Chalmers, 2012), is also associated with
insulin resistance and diabetes (Li et al., 2008; Chen et al., 2012;
Zhang et al., 2016). The association of the ficolin family with
diabetes is interesting given that the relationship between diabetes
and AD is well documented (Janson et al., 2004; Talbot et al.,
2012).
Whilst Aβ40 and AopC4 were included in minimal
protein panel with optimal accuracy for classifying high
[18F]-flutemetamol PET amyloid from low [18F]-flutemetamol
PET amyloid subjects, the accuracy of the 6-protein classifier was
only modest (AUC = 0.69). Given that the proteins measured
in this study included those that were previously identified as
markers of other AD related measures [including cognitive
decline, CSF Tau/Aβ and brain atrophy (Hye et al., 2014;
Sattlecker et al., 2014)] they may not necessarily be specific to the
load of fibrillised amyloid deposits in brain. Moreover, changes
in CSF Aβ and tau, PET amyloid, MRI measures of brain atrophy
and clinical measures of decline are all detectable at different
stages of disease (Jack et al., 2013). We would therefore not
necessarily expect all of these proteins to be related to amyloid
at the MCI stage. In order to evaluate the biomarker utility of
these proteins further, testing in larger independent cohorts with
measures relating to various aspects of disease pathology and
stage would be useful.
In the GE067-005 study cohort associations of Apo(a),
ApoA-I, Ceruloplasmin and PPY with MCI conversion to
AD were observed, and increased levels of ApoA-I were also
tending toward an association with high [18F]-flutemetamol
PET. All four proteins have previously been suggested as
putative blood markers related to AD. For example, Apo(a)
has previously been shown to be increased with high PiB
PET amyloid (Ashton et al., 2015). Whilst increased plasma
ApoA-1 in association with cognitive decline (Thambisetty
et al., 2010; Song et al., 2012) and brain atrophy (Hye
et al., 2014) have been observed. Decreased ApoA-1 levels
in AD versus controls (Liu et al., 2006; Shih et al., 2014)
and in association with increased risk of clinical progression
to MCI and AD (Slot et al., 2017) and PiB PET amyloid
(Ashton et al., 2015; Westwood et al., 2016) have also been
shown. Moreover, ApoA-1 has been implicated in amyloid
pathology, binding Aβ and protecting hippocampal neuronal
cultures from Aβ-induced neurodegeneration (Paula-Lima et al.,
2009).
In this study we use a range of proteomics approaches,
building on previous studies from our group and others that have
indicated a protein signature in blood that differentiates disease
from non-disease and measures correlates with ‘endophenotypes’
of that disease state, as previously reviewed (Thambisetty
and Lovestone, 2010; Baird et al., 2015; Shi et al., 2017).
Others have taken a more direct route to blood biomarkers
of AD, seeking to measure amyloid directly. Early studies
using immunocapture were largely unsuccessful in identifying
a marker methodology that predicted brain amyloid and
was stable across studies and disease phases. More recently,
using mass spectrometry and immunocapture with novel
antibodies studies have reported excellent power in predicting
brain amyloid load (Pesini et al., 2012; Ovod et al., 2017;
Nakamura et al., 2018). However, whilst these studies show
enormous potential, in some cases the methods are not yet
suitable for application at scale, in large multi-site studies,
require bespoke sample collection protocols and are likely
to be resource intensive. These studies have however, clearly
confirmed the findings of early biomarker studies that there is
a signature in blood that reflects disease pathology. The use
of multiplexed immunocapture as we describe here is a low-
cost technology, readily applicable in the context of very large
multi-center trials and therefore may have real world utility
alongside any other approach to blood based biomarkers being
developed.
In conclusion, in this study we have identified a number of
proteins that are associated with CSF Aβ42/tau pathology. We
identified and replicated FCN2 as a novel biomarker of both CSF
and PET measures of AD pathology in an independent cohort
and by independent proteomic platforms. Furthermore, we find
an association of C4 with [18F]-flutemetamol PET amyloid and
four proteins; Apo(a), ApoA-I, Ceruloplasmin and PPY with
MCI conversion to AD, building upon previous findings of their
relationship with AD and amyloid pathology. These results would
suggest a biologically relevant role for these proteins in AD.
Further analysis of the potential of these proteins as a biomarker
of AD pathology and progression, in combination with other
proteins or multimodal measures, and in larger independent
cohorts will be essential. Such a blood-based biomarker could
be of value as a triaging tool for PET and CSF based tests and
hence aid in recruitment to clinical trials of disease modifying
treatments.
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